Drugmaker Biogen is pulling the plug on its controversial Alzheimer’s drug Aduhelm, following disappointing gross sales. It had been anticipated to be a blockbuster product.
MARY LOUISE KELLY, HOST:
A drugmaker is pulling the plug on an Alzheimer’s remedy that was as soon as anticipated to be a blockbuster. NPR’s Sydney Lupkin stories on what occurred and what it may imply for sufferers.
SYDNEY LUPKIN, BYLINE: Aduhelm was purported to be a giant deal. That is as a result of the drug cleared sticky clumps of protein known as amyloid from the brains of sufferers with Alzheimer’s illness. Of the 2 large research of Aduhelm submitted to the Meals and Drug Administration, one discovered that the drug delayed the lack of reminiscence and pondering, whereas the opposite discovered no clear profit. A panel of specialists advising the company advisable in opposition to approval, however the company did it anyway in 2021 with a catch. Biogen, the drug’s maker, needed to do extra analysis to verify Aduhelm labored and get the examine achieved by 2030. Now Biogen says it could not discover a companion or financing to assist pay for the pricey confirmatory examine, so it is reducing its losses and specializing in its different FDA-approved Alzheimer’s drug known as Leqembi. Dr. Aaron Kesselheim from Harvard was one in every of three FDA advisers who resigned in protest over the Aduhelm approval.
AARON KESSELHEIM: The truth that within the intervening three-plus years that there was no extra information that is come out that advised something constructive about this drug is an indicator to me that the advisory committee was appropriate in assessing this drug didn’t have good proof and shouldn’t have been permitted.
LUPKIN: Aduhelm by no means took off. Biogen initially set its worth at $56,000 a yr, however demand was so weak the corporate slashed the worth in half just a few months later. Medicare additionally restricted protection for Aduhelm to sufferers who had been in scientific trials. Nonetheless, Biogen’s determination to withdraw Aduhelm was surprising. Heather Snyder from the Alzheimer’s Affiliation says sufferers had been nonetheless being enrolled within the confirmatory examine when Biogen made its announcement. However she says there is a silver lining.
HEATHER SNYDER: The approval of Aduhelm was a landmark occasion that actually supplied hope for therefore many people which are or had been dwelling with early Alzheimer’s and their households.
LUPKIN: And different experimental Alzheimer’s medicine are shifting ahead within the pipeline. Biogen says sufferers presently taking Aduhelm could have entry to it till November 1, however sufferers taking the drug in scientific trials will lose entry Might 1. Biogen had licensed the drug from a Swiss biotech known as Neurimmune. Neurimmune says it is going to proceed to work on the drug and goals to hunt approval for a model that’s given by injection as an alternative of infusion.
Sydney Lupkin, NPR Information.
(SOUNDBITE OF MUSIC)
Copyright © 2024 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional data.
NPR transcripts are created on a rush deadline by an NPR contractor. This textual content will not be in its closing type and could also be up to date or revised sooner or later. Accuracy and availability might differ. The authoritative report of NPR’s programming is the audio report.